News and Trends 3 Apr 2020 Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M Eli Lilly will partner Oxford-based Sitryx to develop up to four drug candidates to treat autoimmune disease in a deal worth €811M if development milestones are met. The UK biotech… April 3, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2020 Late-Stage Success Raises Hopes to Tackle Alzheimer’s via Inflammation …tests. The test subjects took the candidate in addition to standard Alzheimer’s disease medications. Masitinib is a drug that inhibits tyrosine kinase proteins, which are involved in promoting inflammation. The… December 21, 2020 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2017 British Biotech Tops up its Cancer Pipeline with New TCR Therapy Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all… June 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Expert Advice 23 Feb 2024 Navigating the life sciences job market: Five job boards making your life easier …strongly believes in specialized job boards and thinks the setback of traditional job boards is that they can easily get overcrowded, making it tough for candidates to get noticed and… February 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 22 Jul 2019 Turning Shelved Drugs into a New Promise for Immuno-Oncology After working for 12 years at Merck, Catherine Pickering decided to take a risk and create iOnctura, a spin-out company exploring a new application in immuno-oncology for a drug candidate… July 22, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 29 Jan 2025 Pancreatic cancer: Oncolytics Biotech, Candel, and CytomX bring promising therapies to the clinic …cancers showing high expression of EGFR. The candidate in question here is called CX-904. Being a bispecific antibody, it targets both EGFR on cancer cells and the CD3 receptor on… January 29, 2025 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Domain Therapeutics to start clinical trials of solid tumor treatment Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM… October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases? …candidate, MIN-102, for X-linked Adrenoleukodystrophy, spun out Gain Therapeutics last week. This new biotech will use a platform called SEE-Tx to develop pharmacological chaperones for rare metabolic diseases. These small… February 28, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 French Biotech Takes its Oral Diabetes Drug to Phase III …key secondary endpoints in a Phase IIb study in Japan for its type 2 diabetes candidate Imeglimin. Now, the company plans to go for a Phase III program that could… March 13, 2018 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2020 Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder …US private equity investors. The Swiss company will use the money to progress its lead candidate treatment for autism spectrum disorder into a phase Ib clinical trial this year. The… February 4, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2019 Update: The FDA Green-lights Clinical Trials for Huntington’s Disease Gene Therapy …the US in late 2019. Published on 23/01/2018: The EMA has given uniQure’s gene therapy candidate for Huntington’s disease Orphan Medicinal Product Designation, which the company hopes to move into… January 23, 2019 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 20 Dec 2018 Cambridge Company Raises €20M for Potential First in Lung Disease …until its acquisition in 2017, had a big phase III failure with a drug candidate for the same condition. The lead candidate of Morphogen-IX is a protein, called bone morphogenetic… December 20, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email